News

Sotatercept (ACE-011) leads to clinically meaningful reductions in heart strain and improvements in functional capacity in patients with pulmonary arterial hypertension (PAH), top-line data from a Phase 2 trial show. The findings were presented in an oral presentation, titled “Sotatercept for…

Anodal block, a technique based on electrical nerve stimulation, allows for the selective activation of fibers in the vagus nerve, a key nerve that runs through the neck and controls the workings of the heart and lungs, an early study in mice reported. A more controlled activation of the vagus…

Newborns were seen to be at an increased risk of pulmonary hypertension (PH) if they developed poorly while in the womb and had meconium aspiration syndrome, meaning they inhaled their feces during birth, a study from Pakistan reported.  The…

The Alexion Charitable Foundation has awarded $1.1 million in grants to programs that support those with rare diseases during the COVID-19 pandemic, the organization recently announced. The grants will support activities that align with the foundation’s Rare Belonging focus, a set of funding priorities aimed at improving the…

Increasing the levels of a tiny RNA molecule known as microRNA-483 enhanced the function of endothelial cells and eased the symptoms of pulmonary arterial hypertension (PAH) in rat models of the disease, a new study shows. The results support the potential of microRNA-483 as a potential therapy for PAH. The study,…

Gene expression patterns in the lungs can help distinguish pulmonary arterial hypertension (PAH) from pulmonary veno-occlusive disease (PVOD) — a subtype in which the narrowing of veins, instead of arteries, causes pulmonary hypertension — with high accuracy, a study reported. Findings also showed that lung diseases share similar alterations…

Kalytera Therapeutics has announced positive early results for R-107, a liquid form of nitric oxide designed to treat pulmonary arterial hypertension (PAH) associated with COVID-19. Nitric oxide, known as NO, is a gas naturally present in the…

Aerami Therapeutics has entered an agreement with Vectura Group to develop and commercialize an inhaled form of imatinib — an approved cancer therapy — for the treatment of people with pulmonary arterial hypertension (PAH). Under the agreement, Aerami will be solely responsible for developing this new…

CAR peptide (CAR), Vascular BioSciences’ lead therapeutic peptide candidate for pulmonary hypertension (PH) and other disorders, was found to increase the efficacy of Remodulin (treprostinil) at reducing clinical signs of PH and prolonging the survival of a rat model of the disease. These preclinical findings were…

The Black Women’s Health Imperative (BWHI) recently created a Rare Disease Diversity Coalition focused on reducing racial disparities in the rare disease community. Getting a timely and accurate diagnosis for a disease that few people — sometimes even physicians — have heard of is challenging on its own merit.

People with pulmonary arterial hypertension (PAH) who were treated with Uptravi (selexipag) had a lower risk and rate of hospitalization than those taking Orenitram (treprostinil), a real-world analysis revealed. The study,…

Six weeks of treatment with levosimendan significantly lowered pressure on the heart and improved physical capacity among people with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF), findings from a Phase 2 trial show. The investigational treatment, by Tenax Therapeutic, however, did…